General Fluidics is a medical technology company headquartered in Waltham, Massachusetts, specializing in blood diagnostic devices. Founded in 2013, the company offers the Axess Point of Care testing platform that integrates hematology, clinical chemistry, and immunoassay tests, enhancing diagnostic capabilities for various healthcare facilities. General Fluidics' mission is to provide comprehensive diagnostic solutions that are both high-quality and accessible, aimed primarily at improving patient outcomes at the point of care.
| Attribute | Information |
|---|---|
| Founding Date | 2013 |
| Headquarters | Waltham, Massachusetts, United States |
| Founders | Information not readily available |
| Revenue | Information not publicly disclosed |
| Profits | Information not publicly disclosed |
| Key Investors | Unattributed - II (latest funding round) |
| Industry | Medical Technology |
| Number of Employees | Information not readily available |
General Fluidics was founded in 2013 with the vision of revolutionizing blood diagnostics by making them more accessible and comprehensive. Initially, the focus was on developing a fully integrated point-of-care testing platform that could deliver the accuracy of traditional lab equipment. The founders identified a gap in the market for portable diagnostics that could provide rapid results outside conventional laboratory settings. Over the early years, the company invested heavily in R&D to combine hematology, clinical chemistry, and immunoassay tests into a single platform.
General Fluidics' business model centers around enhancing the point-of-care diagnostic process. The Axess platform is designed to provide healthcare professionals with critical diagnostic information quickly and efficiently. Throughout its development, General Fluidics has achieved several key milestones:
General Fluidics is actively working to expand its market presence globally. The company leverages its unique testing platform to compete effectively in the diagnostic testing space. The focus remains on improving healthcare outcomes by providing swift and accurate diagnostic results, thereby reducing the time from testing to treatment. While specific market share data is not available, General Fluidics positions itself as a leader in innovative point-of-care solutions, continuing to explore partnerships and collaborations to enhance its offerings.
General Fluidics has established itself as a formidable player in the medical diagnostics industry, particularly in the realm of point-of-care testing. By continually innovating its Axess platform, the company has catered to the evolving needs of healthcare providers, offering a versatile and efficient diagnostic solution. As the healthcare landscape continues to prioritize patient outcomes and swift diagnostic processes, General Fluidics is well-positioned to maintain its growth trajectory and expand its impact on global healthcare practices.